Abstract
Chinese patent medicine (CPM), developed upon therapeutic theories of traditional Chinese medicine (TCM), is mostly composed of complicated formula. The quality standard of this kind of medicine, as a whole, cannot be used to evaluate its therapeutic value; it can only be used to control the quality of the final products. This is due to the fact that no single active constituent of any crude herbal drug in the medicinal product can be responsible for the entire therapeutic activity of such a complicated formula in the treatment of “Zheng” (roughly corresponds to “syndrome”). Therefore the quality standards of Chinese patent medicine are different from that of chemical pharmaceuticals upon which the therapeutic value and side effects of the product can be evaluated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Reference
Chinese Pharmacopoeia (Volume 1), 2000 p.249
Xie Peishan On Integration of Traditional Chinese Medicine Culture and The Scientific Quality Control, J. of Integration of Chinese Medicine and Western Medicine 1998, 18 (11)645–647
Philipsom J. D. British Herbal Pharmacopoeia. British Herbal Medicine Association Publications. 1996 Forward
Indian Drug Manufacturere’s Association. Indian Herbal Pharmacopoeia. Vedams Books International. 1998 Volume 1
Branka Barl. Quality Analysis and Standardized Extracts of Medicinal Herbs. PMAP Conference 1997 (from Internet)
Rudolf Bauer. Quality Criteria and Phytopharmaceuticals: Can Acceptable Drug Standards be achieved? Drug Information Journal. 1998, 32: 101–110
Natalie Lazarowych. Use of Fingerprinting and Marker Compounds for Identification and Standardization of Botanical Drugs: Strategies for Applying Pharmaceutical HPLC Analysis to Herbal Products. Drug Information Journal. 1998, 32: 497–512
Peter John Houghton. Establishing Identification Criteria for Botanicals. Drug Information Journal, 1998,32:461–469
WHO. Guidelines for the Assessment of Herbal Medicines 1996
Xie Peishan, Yan Yuzhen. HPTLC Fingerprint Identification of Ginseng, High Resolution Chromatography & Chromatography Communication, 1987, 10(11): 607~610
Xie Peishan, Yan Yuzhen. Differentiation & Evaluation of Commercial Ginseng & Their Products by Means of HPTLC Fingerprint Analysis, 1988, 1(1): 29~32
Xie Peishan, Yan Yuzhen. Application of HPTLC Fingerprint Analysis to Stability Evaluation of Ginseng Preparations, Journal of Planar Chromatography- Modern TLC. 1988, 1(3): 258
Xie Peishan, Yan Yuzhen. Optimization of the TLC of Protoberberine Alkaloids and Fingerprint valuation of the Coptidis Rhizome, Journal of Planar Chromatography-Modern TLC. 1992, 5 (5): 302–307
O. Sticher. Quality of Ginkgo preparations. Planta Medica. 1993, (59): 2–11
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Xie, P., Yan, Y. (2001). On the Quality Assessment of Chinese Patent Medicine. In: Lin, Y. (eds) Drug Discovery and Traditional Chinese Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1455-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1455-8_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5562-5
Online ISBN: 978-1-4615-1455-8
eBook Packages: Springer Book Archive